Disc Medicine, Inc. (NASDAQ:IRON) CEO Sells $304,228.92 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 5,574 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the completion of the transaction, the chief executive officer now owns 154,828 shares in the company, valued at $8,450,512.24. The trade was a 3.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON traded down $0.11 on Thursday, reaching $54.35. The company’s stock had a trading volume of 369,811 shares, compared to its average volume of 402,546. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The company has a market cap of $1.62 billion, a P/E ratio of -13.66 and a beta of 0.73. The company has a 50-day simple moving average of $59.46 and a 200 day simple moving average of $55.02.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently made changes to their positions in IRON. Sterling Capital Management LLC lifted its holdings in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Disc Medicine in the 4th quarter worth about $40,000. Tower Research Capital LLC TRC lifted its holdings in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Disc Medicine in the 3rd quarter worth about $131,000. Institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on IRON shares. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $88.90.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.